Su, P., Yang, S., Chen, Y., Wu, Y., Lin, C., Chang, W., . . . Su, W. (2019). Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment. Cancer Med.
Chicago Style citaatSu, Po‐Lan, et al. "Real‐world Outcomes of NSCLC Patients Receiving Tissue or Circulating Tumor DNA‐guided Osimertinib Treatment." Cancer Med 2019.
MLA citatieSu, Po‐Lan, et al. "Real‐world Outcomes of NSCLC Patients Receiving Tissue or Circulating Tumor DNA‐guided Osimertinib Treatment." Cancer Med 2019.
Let op: Deze citaties zijn niet altijd 100% accuraat.